EXACT SCIENCES CORPORATION

(EXAS)
  Report
Delayed Nasdaq  -  04:00 2022-07-01 pm EDT
41.13 USD   +4.42%
06/30EXACT SCIENCES : Purchase Agreement - Form 8-K
PU
06/24EXACT SCIENCES CORPORATION(NASDAQCM : EXAS) added to Russell 2500 Index
CI
06/24EXACT SCIENCES CORPORATION(NASDAQCM : EXAS) added to Russell 2500 Growth Index
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/27/2022 06/28/2022 06/29/2022 06/30/2022 07/01/2022 Date
44.1(c) 41.11(c) 40.58(c) 39.39(c) 41.13(c) Last
1 633 149 2 261 021 1 190 754 1 748 173 1 460 291 Volume
-2.33% -6.78% -1.29% -2.93% +4.42% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 2 009 M - -
Net income 2022 -761 M - -
Net Debt 2022 1 963 M - -
P/E ratio 2022 -9,55x
Yield 2022 -
Sales 2023 2 348 M - -
Net income 2023 -597 M - -
Net Debt 2023 2 124 M - -
P/E ratio 2023 -12,3x
Yield 2023 -
Capitalization 7 237 M 7 237 M -
EV / Sales 2022 4,58x
EV / Sales 2023 3,99x
Nbr of Employees 6 460
Free-Float 99,1%
More Financials
Company
Exact Sciences Corporation is a global cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection. It offers laboratory testing services from its Cologuard colorectal cancer screening test, Oncotype DX cancer diagnostic tests and services, and COVID-19 test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA)... 
More about the company
Ratings of Exact Sciences Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about EXACT SCIENCES CORPORATION
06/30EXACT SCIENCES : Purchase Agreement - Form 8-K
PU
06/24EXACT SCIENCES CORPORATION(NASDAQCM : EXAS) added to Russell 2500 Index
CI
06/24EXACT SCIENCES CORPORATION(NASDAQCM : EXAS) added to Russell 2500 Growth Index
CI
06/24EXACT SCIENCES CORPORATION(NASDAQCM : EXAS) added to Russell 2500 Value Index
CI
06/21TRANSCRIPT : Exact Sciences Corporation Presents at Nephron Liquid Biopsy Innovation Sympo..
CI
06/21Exact Sciences Enters Into Long-Term Supply Agreement With Ultima Genomics
MT
06/21Ultima Genomics and Exact Sciences enter long-term supply agreement aimed at improving ..
PR
06/13TRANSCRIPT : Exact Sciences Corporation Presents at Goldman Sachs 43rd Annual Global Healt..
CI
06/10Declaration of Voting Results by Exact Sciences Corporation
CI
06/08TRANSCRIPT : Exact Sciences Corporation Presents at 2022 Jefferies Global Healthcare Confe..
CI
06/06TRANSCRIPT : Exact Sciences Corporation Presents at William Blair’s 42nd Annual Growt..
CI
06/06PureTech Health Reports Appointment of COO at Its Akili Interactive Labs
MT
06/03WALL STREET STOCK EXCHANGE : Elon still rules over markets
06/03ANALYST RECOMMENDATIONS : Micron, Microsoft, Snowflake, Solaredge, Veeva Systems...
06/03Piper Sandler Starts Exact Sciences at Neutral With $50 Price Target
MT
More news
News in other languages on EXACT SCIENCES CORPORATION
06/21Exact Sciences conclut un accord d'approvisionnement à long terme avec Ultima Genomics
05/02Exact Sciences Corporation a finalisé l'acquisition d'Omicera Diagnostics Gmbh.
04/29Exact Sciences Corporation a reçu une proposition d'actionnaire de James McRitchie
04/29Les lignes directrices de l'American Society of Clinical Oncology recommandent fortemen..
04/27MISE À JOUR SECTORIELLE : Les actions du secteur de la santé affichent de petits gains ava..
More news
Analyst Recommendations on EXACT SCIENCES CORPORATION
More recommendations
Chart EXACT SCIENCES CORPORATION
Duration : Period :
Exact Sciences Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXACT SCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Last Close Price 41,13 $
Average target price 93,35 $
Spread / Average Target 127%
EPS Revisions
Managers and Directors
Kevin T. Conroy Chairman, President & Chief Executive Officer
Jeffrey Thomas Elliott Executive VP, Chief Operating & Financial Officer
Sandra Statz Senior VP-Clinical & Regulatory Affairs
Gary Frings Chief Information Officer
Paul J. Limburg Co-Chief Medical Officer
Sector and Competitors